Pancreatic neuroendocrine neoplasms: diagnosis and management.
Pancreatic neuroendocrine neoplasms are uncommon but rising in incidence. There have been recent changes in the WHO nomenclature and a newly proposed American Joint Committee on Cancer TNM staging, which complement each other. These neoplasms are of great medical and radiological interest because of their diverse presenting features and imaging appearances. There is an increased role for both anatomic and functional imaging in the assessment of these neoplasms. A review of the nomenclature, staging, and imaging is presented in this paper.
Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Unit 1473, P.O. Box 301402, Houston, TX 77030, USA. abalachandran@mdanderson.org
Aparna
A
Balachandran
Eric P
EP
Tamm
Priya R
PR
Bhosale
Madhavi
M
Patnana
Raghu
R
Vikram
Jason B
JB
Fleming
Matthew H
MH
Katz
Chuslip
C
Charnsangavej
D018278:Carcinoma, Neuroendocrine / Q000175:diagnosis* / Q000556:secondary / Q000601:surgery*; D019160:Endosonography; D015408:Gastrinoma / Q000175:diagnosis; D005765:Gastrointestinal Agents; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008279:Magnetic Resonance Imaging; D018761:Multiple Endocrine Neoplasia Type 1; D009367:Neoplasm Staging; D015282:Octreotide; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery*; D049268:Positron-Emission Tomography; D017481:Receptors, Somatostatin / Q000378:metabolism; D009626:Terminology as Topic; D003969:Vipoma / Q000175:diagnosis
D005765:Gastrointestinal Agents; D017481:Receptors, Somatostatin; D015282:Octreotide